Federal Circuit Affirms PTAB Finding that Dupixent® Immunex Patent is Obvious
By EsqSocial Corporation 27/10/20
As previously reported, in February 2019, the Patent Trial and Appeal Board issued final written decisions in two IPR proceedings initiated by Sanofi challenging the U.S. Patent No. 8,679,487 (the ’487 patent) owned by Immunex. In IPR2017-01884, the Board held that the challenged claims of the ‘487 patent were unpatentable in view of the grounds raised by Sanofi, but it came to the opposite conclusion in IPR2017-01879....
By: Goodwin